Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...
-inc-logo-1200x675.jpg?v=20240515130629){kind=logo}
Definium Therapeutics (NASDAQ:DFTX) reported first-quarter 2026 financial results and outlined a series of near-term clinical milestones for its lead candidate, DT120 ODT, during a conference call held...
Three Phase 3 topline data readouts for DT120 ODT expected in the coming months DT120 ODT program expanded into PTSD with Phase 3 Haven study expected to initiate in...
Barchart Research What to Expect from DFTX Earnings DFTX Generated May 6, 2026 Current Price $23.42 EPS Estimate $$-0.47 Consensus Rating Strong Buy Average Move 4.80% Definium Therapeutics Prepares to...
Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological...
Psychedelic drugs could get a big boost thanks to a recent executive order, and these firms all have promising candidates in line.
MDD: Emerge topline data readout on track for late 2Q 2026; Ascend sites activated with first patient dosing anticipated in 2Q 2026 GAD: Voyage enrollment complete with...
Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...
Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapies targeting the underlying causes of psychiatric...
Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological...